90%Confidence
0Views
FDASource
2026-03-10Date
Summary
Vista Meibo Tears recall completes a pattern of sterility failures across Wizcure's Vista brand eye drops distributed by hi-health. This suggests comprehensive manufacturing quality breakdown requiring urgent remediation and possible FDA regulatory action.
Actionable: Avoid investment in hi-health or Wizcure Pharmaa until independent audits confirm resolution of their sterility assurance programs.
AI Confidence: 90%
Data Points
firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productVista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula, 10 ml (1/3 fl.oz.), Wizcure Pharmaa PVT. LTD., H-8
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now